SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Dec. 12, 2005--Hana Biosciences (AMEX:HBX): Hana Biosciences (AMEX:HBX), a biopharmaceutical company focused on advancing cancer care, announced today that the Food and Drug Administration has cleared its Investigational New Drug (IND) application for Zensana(TM). Hana is initiating today a series of pivotal pharmacokinetic trials, including comparison of Zensana(TM) to the commercially available ondansetron tablet (Zofran(R); GlaxoSmithkline). Hana expects to complete these pivotal trials by early 2006 and plans to file the New Drug Application (NDA) shortly thereafter. Commercial launch of Zensana(TM) is targeted for 2007.
